Skip to main content
SpringerLink
Log in

A number of levodopa-based strategies may improve the management of motor complications in Parkinson’s disease

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Antonini A, Chaudhuri KR, Martinez-Martin P, et al. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010; 24(2): 119–29

    Article  PubMed  CAS  Google Scholar 

  2. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348(14): 1356–64

    Article  PubMed  CAS  Google Scholar 

  3. Agid Y, Ahlshog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord 1995; 14(6): 911–3

    Article  Google Scholar 

  4. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 2002; 359(9317): 1589–98

    Article  PubMed  Google Scholar 

  5. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Related Dis 2001; 8(2): 95–100

    Article  CAS  Google Scholar 

  6. Marsden CD, Parkes JD, Quinn N. Fluctuations disability in Parkinson’s disease: clinical aspects. In: Masden CD, Fahn S, editors. Movement disorders. London: Butterworth, 1982: 96–122

    Google Scholar 

  7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study. Brain 2000; 123 Pt 11: 2297–305

    Article  PubMed  Google Scholar 

  8. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 2009; 8(10): 929–37

    Article  PubMed  CAS  Google Scholar 

  9. DeGaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiat 2006; 77(4): 450–3

    Article  CAS  Google Scholar 

  10. Derost PP, Ouchchane L, Morand D, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007; 68(17): 1345–55

    Article  PubMed  Google Scholar 

  11. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998; 65(5): 709–16

    Article  PubMed  CAS  Google Scholar 

  12. Metman LV, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994; 9(4): 463–5

    Article  PubMed  CAS  Google Scholar 

  13. Stocchi F, Barbato L, Bramante L, et al. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind crossover study versus placebo. Funct Neurol 1994; 9(5): 259–64

    PubMed  CAS  Google Scholar 

  14. Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007; 30(1): 18–24

    Article  PubMed  CAS  Google Scholar 

  15. Djaldetti R, Giladi N, Hassin-Baer S, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson’s disease: an open-label, randomized, crossover study. Clin Neuropharmacol 2003; 26(6): 322–6

    Article  PubMed  CAS  Google Scholar 

  16. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol 1988; 23(6): 589–95

    Article  PubMed  CAS  Google Scholar 

  17. Sage JI, Sonsalla PK, McHale DM, et al. Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson’s disease. Adv Neurol 1990; 53: 383–6

    PubMed  CAS  Google Scholar 

  18. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64(2): 216–23

    Article  PubMed  CAS  Google Scholar 

  19. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007 15 (8); 22: 1145–9

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A number of levodopa-based strategies may improve the management of motor complications in Parkinson’s disease. Drugs Ther. Perspect 26, 10–13 (2010). https://doi.org/10.2165/11205240-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205240-000000000-00000

Search

Navigation